The serotonin 5-HT2C receptor and the non-addictive nature of classic hallucinogens
This review (2016) investigates and proposes a model how psychedelics work in the brain, specifically with regards to the 5-HT (serotonin) 2C receptor. The authors also explain how this mechanism may work to treat addiction.
Authors
- Canal, C. E.
- Murnane, K. S.
Published
Abstract
Classic hallucinogens share pharmacology as serotonin 5-HT2A, 5-HT2B, and 5-HT2C receptor agonists. Unique among most other Schedule 1 drugs, they are generally non-addictive and can be effective tools in the treatment of addiction. Mechanisms underlying these attributes are largely unknown. However, many preclinical studies show that 5-HT2C agonists counteract the addictive effects of drugs from several classes, suggesting this pharmacological property of classic hallucinogens may be significant. Drawing from a comprehensive analysis of preclinical behavior, neuroanatomy, and neurochemistry studies, this review builds rationale for this hypothesis, and also proposes a testable, neurobiological framework. 5-HT2C agonists work, in part, by modulating dopamine neuron activity in the ventral tegmental area-nucleus accumbens (NAc) reward pathway. We argue that activation of 5-HT2C receptors on NAc shell, GABAergic, medium spiny neurons inhibits potassium Kv1.x channels, thereby enhancing inhibitory activity via intrinsic mechanisms. Together with experiments that show that addictive drugs, such as cocaine, potentiate Kv1.x channels, thereby suppressing NAc shell GABAergic activity, this hypothesis provides a mechanism by which classic hallucinogen-mediated stimulation of 5-HT2C receptors could thwart addiction. It also provides a potential reason for the non-addictive nature of classic hallucinogens.
Research Summary of 'The serotonin 5-HT2C receptor and the non-addictive nature of classic hallucinogens'
Introduction
Canal and colleagues review the pharmacology and addiction-related properties of classic hallucinogens (CH), a class that includes tryptamines (for example psilocybin, DMT), ergolines (LSD), and phenylalkylamines (for example mescaline, DOB). They emphasise that CH share high-affinity agonism at serotonin 5-HT2 GPCR subtypes (5-HT2A, 5-HT2B, 5-HT2C) and that blockade of 5-HT2 receptors attenuates many of their psychoactive effects. Despite these shared pharmacological features, CH are generally reported by experienced users and by controlled preclinical studies to have low addiction liability, a contrast to many other Schedule I substances; the mechanistic basis for this apparent non-addictive profile remains uncertain. This paper sets out to synthesise behavioural, neuroanatomical and neurochemical preclinical findings and to propose a testable neurobiological framework that could explain both the non-addictive nature of CH and their potential to treat substance dependence. Specifically, the authors develop and defend a hypothesis in which activation of 5-HT2C receptors—particularly on medium spiny GABAergic neurons in the nucleus accumbens (NAc) shell—modulates intrinsic neuronal excitability (via inhibition of Kv1.x potassium channels), thereby suppressing mesolimbic dopamine signalling that underlies addictive behaviours.
Expert Research Summaries
Go Pro to access AI-powered section-by-section summaries, editorial takes, and the full research toolkit.
Study Details
- Study Typemeta
- Journal
- Topic
- APA Citation
Canal, C. E., & Murnane, K. S. (2017). The serotonin 5-HT2C receptor and the non-addictive nature of classic hallucinogens. Journal of Psychopharmacology, 31(1), 127-143. https://doi.org/10.1177/0269881116677104
References (21)
Papers cited by this study that are also in Blossom
Bogenschutz, M. P., Forcehimes, A. A., Pommy, J. A. et al. · Journal of Psychopharmacology (2015)
Bogenschutz, M. P., Johnson, M. W. · Progress in Neuro-Psychopharmacology and Biological Psychiatry (2016)
Bogenschutz, M. P., Pommy, J. A. · Drug Testing and Analysis (2012)
Dyck, E. · Canadian Journal of Psychiatry (2005)
Dyck, E. · Social History of Medicine (2006)
Gonza ´lez-Maeso, J., Weisstaub, N. V., Zhou, M. et al. · Neuron (2007)
Griffiths, R. R., Johnson, M. W., Richards, W. A. et al. · Psychopharmacology (2011)
Halberstadt, A. L. · Behavioural Brain Research (2014)
Hanks, J. B., González-Maeso, J. · ACS Chemical Neuroscience (2012)
Johnson, M. W., Garcia-Romeu, A., Cosimano, M. P. et al. · Journal of Psychopharmacology (2014)
Show all 21 referencesShow fewer
Krebs, T. S., Johansen, P. Ø. · Journal of Psychopharmacology (2012)
Ludwig, A., Levine, J., Stark, L. et al. · American Journal of Psychiatry (1969)
Maclean, K. A., Johnson, M. W., Griffiths, R. R. · Journal of Psychopharmacology (2011)
Majic, T., Schmidt, T. T., Gallinat, J. · Journal of Clinical Psychopharmacology (2015)
Mangini, M. · Journal of Psychoactive Drugs (2011)
Ray, T. S. · PLOS ONE (2010)
Strassman, R. J., Qualls, C .R. · JAMA Psychiatry (1994)
Strassman, R. J., Qualls, C. R., Berg, L. M. · Biological Psychiatry (1996)
Studerus, E., Gamma, A., Kometer, M. et al. · PLOS ONE (2012)
Tomsovic, M., Edwards, R. V. · Journal of Studies on Alcohol and Drugs (1970)
Vollenweider, F. X., Vollenweider-Scherpenhuyzen, M. F. I., Bäbler, A. et al. · NeuroReport (1998)
Cited By (8)
Papers in Blossom that reference this study
Shinozuka, K., Jerotic, K., Mediano, P. A. M. et al. · Translational Psychiatry (2024)
Jaster, A. M., González-Maeso, J. · Molecular Psychiatry (2023)
Rabinowitz, J., Lev-Ran, S., Gross, R. · Frontiers in Psychiatry (2023)
Arnaud, K. O. S. · Drugs Education Prevention and Policy (2021)
Ermakova, A. O., Dunbar, F., Rucker, J. et al. · Journal of Psychopharmacology (2021)
Ortiz, M. I., Gómez-Busto, F. J. · Clinical Neuropsychiatry (2020)
DiVito, A. J., Leger, R. F. · Molecular Biology Reports (2020)
Schindler, E. A. D., Wallace, R. M., Sloshower, J. A. et al. · Frontiers in Pharmacology (2018)
Your Personal Research Library
Go Pro to save papers, add notes, rate studies, and organize your research into custom shelves.